The worldwide incidence of biliary tract carcinoma (BTC; tumours of the bile ducts and gall-bladder) continues to rise with the only potentially curative treatment remaining surgical resection or transplantation, possible in only a minority of patients. Late presentation and a paucity of effective treatments mandate the development of techniques for early lesion detection.
Introduction
Biliary tract carcinoma (BTC) comprises tumours of the gallbladder and bile ducts, the commonest of which is cholangiocarcinoma (CCa), an adenocarcinoma arising from the epithelium of the biliary tract and which is predominantly diagnosed in the 7 th decade of life [1] . CCa affects 1-2 per 100,000 in the UK population [2, 3] although the UK and worldwide incidence continues to rise with associated increasing mortality rates [3] [4] [5] [6] .
CCa can usually be considered to be sporadic but certain recognised predisposing factors have been identified, including primary sclerosing cholangitis (PSC; CCa occurs in up to 40% of PSC patients), prolonged or recurrent biliary infection, liver fluke infection (particularly in areas where Opisthorchis viverrini is endemic [7] cirrhosis, Caroli disease, the presence of choledochal cysts and hepatolithiasis, and carcinogen exposure (dioxins, nitrosamines, alcohol and thorotrast). BTC is also more prevalent in diabetics and smokers [1, 4] . CCa may occur via an adenomadysplasia-carcinoma sequence, although CCa tumour biology remains poorly understood [8, 9] . A number of mutations exist in tissue derived from CCa specimens, including abnormalities in known oncogenes and tumour suppressor genes; however, the frequency of such mutations is difficult to accurately estimate and this information, to date, remains clinically unusable [10] [11] [12] .
Indeterminate biliary strictures present a diagnostic challenge to the investigating clinician. Many pathologies share clinical and radiological findings with the differentiation of BTC, PSC and autoimmune cholangiopathy remaining particularly difficult [13] [14] [15] . Endoscopic retrograde cholangiopancreatography (ERCP) can be utilized following cross-sectional radiological techniques for lesions assessment and biopsy with sensitivity for malignancy of 9-57% [16] [17] [18] [19] . Endoscopic ultrasound is a further well-established technique that can be used in conjunction with fine needle aspiration (FNA) for the visualization and sampling of gallbladder, hilar and extrahepatic lesions, as well as peri-hilar lymph nodes and vessels with a sensitivity The lack of effective treatments for advanced disease mandates the development of techniques for early lesion detection. Whilst efforts to discover effective serum or bile biomarkers for early detection are ongoing, the relative rarity of the disease and the frequent presence of cholestasis and cholangitis which can confound bile assays, have so far limited discovery efforts. have raised CA19-9 levels, but are subsequently found to have benign disease [36] .
Serum bilirubin levels are also an independent predictor of serum CA19-9 levels:
following intervention for cholestasis (with a subsequent drop in serum bilirubin), serum CA19-9 significantly decreases in tandem [36] , thus limiting its specificity in patients presenting with cholestasis or cholangitis. However, if serum CA19-9 levels remain raised after intervention for cholestasis, this is strongly predictive (although not diagnostic) of malignant disease [37] . Depending upon the cut-off value used, CA19-9 has been shown to have a sensitivity range of 78-89% and a specificity range of 67-87% for the diagnosis of BTC [30, 36, 38, 39] . The use of higher serum CA19-9 cut-off levels decreases sensitivity, only allowing diagnosis of CCa to be made at an advanced stage of disease [33] . Further studies have attempted to use serum CA19-9 evaluation to differentiate between PSC-related and CCa-related strictures, and demonstrate wide-ranging but generally low sensitivity and specificity [31, 33, 40] .
Further, the absolute value of CA19-9 may be affected by the specific assay used, with one study showing that different commercial assays deliver different results, potentially affecting the ability of CA19-9 to discriminate between malignant and benign disease [41] . One method for improving the diagnostic accuracy of CA19-9 may be to combine it with other biomarkers, such as bile-derived galectin- Table 1 ).
Interleukin-6 (IL-6)
IL-6 is a major inflammatory cytokine, whose high serum levels have been shown to correlate well with CCa tumour burden, both pre-and post-surgical resection [45] .
However, high values can also be found in patients with associated inflammatory processes, such as cholestasis and cholangitis, as well as in hepatocellular carcinoma (HCC), metastatic liver lesions, and some benign liver pathologies [35] . Combining its use with CA19-9 (or other biomarkers) may improve its diagnostic accuracy. One group of authors demonstrated that at a cut-off level of 25.8 pg/mL, IL-6 had a diagnostic sensitivity and specificity of 73% and 92% respectively (PPV and NPV 83% and 87%, respectively), when utilized to differentiate between 26 CCa, 26 HCC and 23 healthy patients [46] . Serum levels were shown to correlate closely with tumour burden and also to decrease after treatment with photodynamic therapy.
Similarly, the sensitivity and specificity for serum IL-6 (cut-off value 0.18 ng/mL) in 45 CCa patients was 71% and 90% for the differentiation of CCa and benign liver disease (n=10), whereas the specificity for differentiating from 25 other hepatic tumours (15 HCC, 15 metastatic liver cancer) was only 26.7% [47] . A combination of leucine-rich alpha-2 glycoprotein 1 (LRG-1), CA19-9 and IL-6 was also shown to be capable of discriminating CCa from benign biliary pathology with high diagnostic accuracy [48] .
Mucins
Mucins are cell-specific, high molecular weight, heavily O-glycosylated glycoproteins expressed by ductal and glandular epithelia. They can be found in either transmembrane or secreted forms and have roles in epithelial protection, cellular adhesion and signal transduction. CCa neoplasms are commonly mucin-producing adenocarcinomas in which abnormal expression of various mucins, including mucin1 (MUC1) and mucin5AC (MUC5AC), has been demonstrated and linked to poor outcomes. Importantly, MUC5AC expression has been confirmed in serum from CCa Serum MUC5AC was similarly measured in 179 CCa patients, where it was significantly associated with blood group A, tumours over 5cm in size and advanced disease, as well as poorer prognosis, as compared with patients not expressing serum MUC5AC (median survival, 127 vs. 329 days; P < 0.001) [52] . Those patients expressing serum MUC5AC also had a 2.5 times increased risk of death (p<0.001).
In further support for the potential role of mucins in CCa biology, MUC1 positivity was present in 65.8% of tumours obtained from 34 patients with intrahepatic CCa, 51
with extrahepatic CCa, 11 with gallbladder cancer and 14 patients with pancreatic adenocarcinoma, where it was associated with poor differentiation (p=0.002), T status (p=0.003) and poor patient survival (p=0.015) [53] . In the same study, MUC5AC was associated with advanced tumours (p=0.013) and MUC6 with well-differentiated CCa (p=0.006).
CYFRA21-1
CYFRA21-1 is a soluble fragment of cytokeratin 19, the intermediate filament protein
that forms a crucial part of the epithelial cell cytoskeleton and is therefore constitutively expressed in many epithelial cells. It has been shown to be elevated in many different tumours including cervical, oesophageal and breast, but has a particular biomarker role in non small-cell lung carcinoma [54, 55] . for CCa at a cut-off value of 2.7 ng/mL. Furthermore, the 3-year recurrence-free survival rates were significantly worse in CCa patients with high serum CYFRA21-1 values (25.0% vs. 76.2%) and CYFRA21-1 was found to be independently associated with recurrence and death following surgery on multivariate analysis [56, 57] . It has subsequently been postulated that raised CYFRA21-1 serum levels may represent a high burden of circulating tumour cells and that performing local operative resections in the presence of raised CYFRA21-1 may therefore prove futile [56] .
However, another study group evaluated CYFRA21-1 in 66 patients with BTC (6 PSC-related), 39 patients with benign biliary disease and 19 patients with PSC to
show that at a cut-off value of 1.5 ng/mL, CYFRA21-1 had a sensitivity and specificity of 56% and 88%, respectively, as compared to 79% and 78% for CA19-9
(cut-off value 37 IU/mL), concluding that it was less useful than CA19-9 [58] . A higher cut-off value for CYFRA21-1 (3 ng/mL) improved specificity, but decreased sensitivity (97% and 30% respectively). Combining CYFRA21-1 and CA19-9 (cutoff values 1.5 ng/mL and 37 IU/mL, respectively) led to a sensitivity and specificity of 45% and 96% and a high level of CYFRA21-1 (>3.0 ng/mL) was a strong predictor of reduced median survival (2 vs. 10 months; p<0.001) [58] .
Trypsinogen
Tumour-associated trypsinogens 1 and 2 are the precursor zymogen forms of the enzyme trypsin and are encoded by the same genes as pancreatic trypsinogen. A recent study demonstrated that serum trypsinogen-2 (PRSS2) was capable of differentiating between CCa and PSC in 84 patients referred for liver transplantation or other hepatic surgery more effectively than CA19-9, when assessed by timeresolved immunofluorometric assay with areas under the ROC curve (AUC) of 0.804 and 0.613, respectively [59] . Trypsinogen-2 was also more effective at differentiating between PSC with and without CCa (AUC 0.759) and results were unaffected by the presence of other inflammatory conditions (e.g. inflammatory bowel disease) or high serum bilirubin levels. This potentially enhances the specificity of PRSS2 for the 
Receptor Binding Cancer Antigen 1 (RCAS1)
RCAS1 is a membrane protein that may participate in suppression of cell proliferation and induction of apoptotic cell death. Raised levels of serum RCAS1 were found in 73.9% of BTC patients (a higher percentage than CA19-9 or CEA), with a specificity of 96%, and it was suggested that it may aid in monitoring recurrence [60] [61] [62] . Its levels were shown to reduce to within normal limits following surgical resection,
were not affected by the presence of cholestasis and remained elevated in some patients where CA19-9 was normal, thereby providing a potential complementarity.
Dickkopf-related protein 1 (DKK1)
DKK1, a secreted protein with cysteine-rich regions involved in multiple cellular processes, via its inhibitory effect on the WNT signaling pathway, has been implicated in both metastatic spread and local invasion in several tumour types. Shi et al showed that DKK1 expression was raised in CCa cell lines, as well as sera and tissues from patients with CCa [63] . DKK 1 expression was also associated with elevated matrix metalloproteinase 9, VEGF-C and metastasis to hepatic hilar lymph nodes. Further, DKK1 was associated with poorer overall survival and time to recurrence on multivariate analysis, even in patients with low risk of recurrence (p<0.05). DKK1 down-regulation via siRNA decreased cell migration and invasiveness, as well as down-regulating MMP9 and VEGF-C expression. [65] . The peaks were all identified as variants of transthyretin (TTR or prealbumin), a largely hepatically-derived 55-kDa protein which functions as a serum and cerebrospinal fluid carrier of thyroxine and thyroid hormones. TTR serum levels were subsequently assessed and confirmed to be decreased in CCa. Combining it with CA19-9 gave a sensitivity and specificity of 98.2% and 100.0% respectively, for differentiating CCa from benign disease.
Other Biomarkers
However, TTR levels are also reduced in liver disease, malnutrition and acute inflammation, as well as other cancers such as ovarian, cervical and endometrial. Li et al investigated levels of serum M2-PK, the dimeric form of the pyruvate kinase isoenzyme M2, which is responsible for energy production within the glycolytic pathway by catalyzing the dephosphorylation of phosphoenolpyruvate to pyruvate.
M2-PK is the predominant isoform found within proliferating cells, such as fibroblasts, embryonic cells and stem cells and has been implicated in the metabolism of various tumour types. In 115 patients with CCa, 85 with benign disease and 120 healthy blood donors, both M2-PK and CA19-9 were significantly higher in those with CCa and M2-PK was more sensitive and specific than CA19-9 for the diagnosis of malignancy (84.2% vs. 68.4% and 90% vs. 75%, respectively) [67] .
Jamnongkan et al investigated oxidized alpha-1 antitrypsin, an oxidative stress indicator for many pathological states, in opisthorchis-related CCa tissue and serum to demonstrate that patients with high tissue levels had a poorer prognosis [68] . Serum levels of oxidized alpha-1 antitrypsin were also significantly raised in patients with heavy infections, advanced periductal fibrosis and CCa, as compared to healthy controls (p<0.001) and raised serum levels had an OR for CCa of 22.0, potentially representing a promising serum marker in areas where opisthorchis infection is 
Bile Biomarkers
Bile provides a rich source of potential CCa biomarkers as it is more local to the tumour than serum. However, its collection remains an invasive process with significant potential complications and its use as a screening tool is therefore limited.
The following reviews putative biomarkers identified within bile.
Insulin-like Growth Factor-1 (IGF1)
Human CCa tissues express IGF1, a 70 amino acid peptide hormone similar in molecular structure to insulin and which plays an important role in growth and anabolic processes, thereby also having a potentially crucial role in tumour development and proliferation [70] . IGF1 levels measured in bile from patients with biliary obstruction undergoing ERCP were up to 20 times higher in patients with extrahepatic CCa (n=29) than those with pancreatic cancer (n=19) or benign biliary abnormalities (bile duct stones, PSC, cholangitis; n=25) (mean, 84.6 nmol/L vs. 5.8
nmol/L vs. 4.1 nmol/L; p<0.001 with an area under the ROC curve of 1.0) [66] .
Serum IGF-1 levels were also measured, but were similar between the three groups.
Elastase
Gene expression analysis, 2D electrophoretic analysis and mass spectrometry of fasting bile samples from patients undergoing ERCP or transhepatic catheterisation for biliary obstruction from malignant or benign causes (CCa or ductal stones ) demonstrated up-regulation of elastase mRNA, protein expression, and elastase activity in CCa compared to gallstone patients. The specific form was found to be elastase 3B, a pancreas-derived 29kDa serine protease, similar to classical pancreatic elastase 1.
Biliary amylase levels were utilized to correct for the presence of pancreaticobiliary reflux and bile elastase/amylase ratios were significantly raised in CCa patients as compared to gallstone patients (0.214+/-0.045 vs. 0.023+/-0.005, respectively; p<0.001) with an area under the ROC curve of 0.877. Moreover, the ratio had a sensitivity and specificity of 82% and 89% respectively, for differentiating malignant and benign causes of biliary obstruction (cut-off value 0.065) [71] . 
Mini Chromosome Maintenance (MCM)

Other Biomarkers
Relative bile fibronectin concentrations (absolute fibronectin level divided by concentration of bile acids) measured in 62 gallstone patients with cholangitis, 5 with benign strictures and 28 with CCa were significantly different between the groups;
and with a cut-off value of 40 ng/µmol, its sensitivity and specificity for the diagnosis of CCa was 57% and 79%, respectively [73] . However, its increase in patients with cholangitis and cholestasis may limit its usefulness for the diagnosis of CCa. Similarly, monoamine oxidase A (MAOA) was assessed in CCa and non-malignant controls to show that its expression correlated with differentiation, invasion and survival and that the MAOA promoter was hypermethylated upstream of the start codon in CCa samples and cell-lines. Further, IL-6 decreased MAOA expression [78] and may also upregulate progranulin expression and secretion via the ERK1/2/RSK1/C/EBPβ in CCa cell-lines and tissues where it increased CCa growth by an Akt-dependant mechanism [79] . patients with a sensitivity of 83% and a specificity of 79% [80] . Further, all of those with CCa in addition to PSC were correctly identified. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 60 
Expert Opinion
Current biomarkers for the diagnosis of BTC have limited sensitivity and specificity, with particular difficulty in distinguishing PSC-related and malignant strictures, potentially contributing to late diagnosis with subsequent high mortality rates. The incorporation of novel analysis techniques, such as digital image analysis (DIA) and fluorescence in situ hybridization (FISH), into management algorithms may enhance the sensitivity of samples taken at ERCP, whilst maintaining the high specificity of brush cytology, which can be difficult to interpret, particularly in patients with PSC [81, 82] . CCa has been associated with mutations in several oncogenes and up to 80% of tumour cells have been shown to exhibit chromosomal aneuploidy [83] . FISH and DIA can therefore be used to assess for the presence of these DNA abnormalities in brush cytology. They have been shown to improve the overall sensitivity for detecting CCa [82] and in PSC, where confirmation of CCa is particularly challenging, presence of polysomy is highly suggestive of CCa [84] . Similarly, techniques capable of assessing DNA-ploidy, such as flow cytometry, may improve the sensitivity of brush cytology [85] . However, such techniques require further validation and their routine use has only been adopted by a few centres [86] .
Similarly, models that combine multiple biomarkers may improve the diagnostic accuracy of existing markers such as CA19-9 and the identification of a suitable biomarker panel that can be incorporated into treatment pathways may provide good diagnostic accuracy in the future.
A key goal in BTC is the discovery and validation of reliable, easily and consistently measurable biomarkers with good sensitivity and specificity. Statistical modelling of a biomarker signature in pancreatic cancer suggests that targeting 85% specificity would be acceptable in an enriched screening population with a cancer risk of <1%, results which may be applicable to specific at-risk groups in BTC (e.g. PSC) [87] . A better understanding of the underlying tumour biology of BTC would facilitate biomarker development. Various molecular processes have been described as being initiated during chronic cholestasis and associated local inflammation, such as that found during PSC, including release of various pro-inflammatory factors such as IL-6
and -8, tumour necrosis factors, tumour growth factors and platelet-derived growth factors into the local environment, which may ultimately lead to DNA damage, apoptotic escape mechanisms and initiation of pro-oncological pathways, such as p53, 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58 combined in a tissue microarray [91] . There was also differential expression of p16, p53 and Bcl-2 between intra-and extrahepatic CCa. p16 levels have subsequently been identified as having prognostic significance [91] [92] [93] [94] , as have the expression levels of epithelial-mesenchymal transition related genes, previously implicated in malignant invasion and poor prognosis [95] and HER3 of the receptor protein tyrosine kinase family [96] . Further, a specific isoform of p53 (∆133p53) has now been identified as being associated with shorter overall survival than alternate p53 isoforms [97] .
However, many of these pathways are crucial to multiple tumour types and little is known of the specific tumour biology underlying BTC development and progression. Other miRNAs, such as miR-320, miR-204 and miR-29b which attenutate proapoptotic pathways, have been shown to be down-regulated [111, 112] . miRNA-21
and -200b are over-expressed in CCa and may also contribute to tumour progression by promoting resistance to chemotherapy [113] .
Many solid tumours, including BTC, are characterized by RNA, DNA and chromosomal abnormalities and the initial work on gene expression, branched clonal evolution and tumour heterogeneity in other tumour types mandates further proteomic, metabolomic and genetic analysis of BTC tumours to aid understanding of tumour biology and facilitate biomarker develoment [114] . Plasma and bile M2-PK concentrations were measured by enzyme-linked immunosorbent assay in 88 patients with BTC, 79 with benign biliary diseases, and 17 healthy controls. Sensitivity (90.3%) and specificity (84.3%) of bile M2-PK for malignancy were significantly higher than those for plasma M2-PK and serum carbohydrate antigen 19-9. Transfection of M2-PK in a negatively expressed cell line (HuCCT-1 cells) increased cell invasion, whereas silencing in an M2-PK-positive cell line (TFK cells) decreased tumor nodule formation and cellular invasion. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  P  e  e  r  R  e  v  i  e  w  O  n  l  y 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 
